New hope for Tough-to-Treat blood cancer patients
NCT ID NCT07184788
Summary
This study is testing whether a combination of three drugs (glofitamab, polatuzumab vedotin, and GemOx) can help control aggressive B-cell lymphoma that has returned or hasn't responded to previous treatment. The trial will enroll 80 adults to see how well the treatment works and how safe it is. Researchers will measure how many patients respond to treatment and how long they live without the cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.